To evaluate the relationship between whole body volumetric (Wbv) results of 68Ga-PSMA PET/CT with biochemical and histopathological parameters.
One hundred twenty-one prostate cancer patients who underwent 68Ga-PSMA PET/CT between January 2018 and December 2019 were included. Imaging was conducted for staging upon new diagnosis with moderate- and high-risk disease and for confirming the progression of castration resistance. The relationships between the Wbv 68Ga-PSMA PET/CT parameters and prostate-specific antigen (PSA) levels, PSA doubling time and Gleason score (GS) were evaluated.
The median GS and mean PSA levels were similar between the castration-naive and resistant patients. The PSA levels were positively correlated with MTVwb (p: 0.009, r: 0.286) and TLPwb (p: 0.002, r: 0.344). Gleason scores were positively correlated with MTVwb (p: 0.050, r: 0.216), TLPwb (p: 0.007, r: 0.296) and highest standard uptake value (HSUV) max (p: 0.047, r: 0.220). In the castration-naive group, Gleason scores (from p < 0.001 to p = 0.04 and r = 0.331 to 0.549) and PSA levels (from p = 0.002 to p = 0.045 and from r = 0.323 to 0.473) correlated with all 68Ga-PSMA-PET/CT parameters. PSA doubling time was negatively correlated with whole-body metabolic tumour volume (MTVwb) (p: 0.050, r: 0.232) and whole-body total lesion PSMA (TLPwb) (p: 0.026, r: 0.262). The MTVwb, TLPwb and HSUVpeak values of the patients with biochemical recurrence (BR) of 0–6 months (n = 18) were higher than those with BR > 2 years (n = 35) (p = 0.046, 0.047 and 0.042, respectively).
Wbv 68Ga-PSMA PET/CT results were correlated with PSA levels and Gleason scores. The correlation was relatively stronger in the castration-naive group. The prognostic accuracy of PSA in the resistant group may be weaker than in the naive group. The difference in volumetric parameters of patients with short BR compared to long BR supports the idea that 68Ga-PSMA PET/CT can distinguish patients with rapid relapse from others.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.
Henderickx MMEL, Brits T, Muilwijk T, Adams T, Vandeursen H. Localized prostate cancer and robot-assisted laparoscopic radical prostatectomy: a retrospective, comparative study between pre- and post-operative Gleason scores. Acta Chir Belg. 2018;118:15–20.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74.
Naccarato AMEP, Consuelo Souto S, Matheus WE, Ferreira U, Denardi F (2018). Quality of life and sexual health in men with prostate cancer undergoing radical prostatectomy. Aging Male 24:1–8. https://doi.org/10.1080/13685538.2018.1486397. Epub ahead of print.
Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906–10.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.
Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–68.
Petersen LJ, Nielsen JB, Langkilde NC, Petersen A, Afshar- Oromieh A, De Souza NM, et al. 68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weightedMRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World J Urol. 2020;38:939–48.
Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, Yücetaş U, Demirdağ Ç, Erdoğan SM, Kabasakal L, Members of Urooncology Association, Turkey. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2018;44:1806–12.
Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68 Ga PSMA I and T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58:1962–8.
Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, et al. 68 GaPSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862–72.
Gafita A, Bieth M, Krönke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT. J Nucl Med. 2019;60:1277–83.
Hijazi S, Meller B, Leitsmann C, Strauss A, Ritter C, Lotz J, et al. See the unseen: mesorectal lymph node metastases in prostate cancer. Prostate. 2016;76:776–80.
Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68 Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934–40.
Henkenberens C, Vonk CA, Ross TL, Bengel FM, Wester HJ, Katja H, et al. (68)Ga-PSMA ligand PET/CT-based radiotherapy for lymph node relapse of prostate cancer after primary therapy delays initiation of systemic therapy. Anticancer Res. 2017;37:1273–9.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, ProPSMA Study Group Collaborators, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.
Medina-Ornelas Sevastián S, García-Pérez Francisco O, Hernández-Pedro Norma Y, Arellano-Zarate Angélica E, Abúndiz-López BL. Correlation between molecular tumor volume evaluated with 68Ga-PSMA PET/CT and prostatic specific antigen levels. Rev Esp Med Nucl Imagen Mol. 2018;37:223–8.
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2019. https://doi.org/10.1016/j.eururo.2019.01.049 (Epub ahead of print 14 February 2019).
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436–43.
van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68gallium-prostate specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119:209–15.
Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RA. Assessment of bone metastases in patients with prostate cancer-a comparison between 99mTc-bone-scintigraphy and [68Ga]Ga-PSMA PET/CT. Pharmaceuticals. 2017;10:68.
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114–21.
Pereira Mestre R, Treglia G, Ferrari M, Pascale M, Mazzara C, Azinwi NC, et al. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: a meta-analysis. Eur J Clin Invest. 2019;49:e13063.
Zou Q, Jiao J, Zou MH, Li MZ, Yang T, Xu L, et al. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer. Abdom Radiol. 2020;9:18.
Qu LG, Nzenza T, McMillan K, Sengupta S. Delays in prostate cancer care within a hospital network in Victoria. Australia ANZ J Surg. 2019;89:1599–604.
Yilmaz U, Komek H, Can C, Altindag S. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax. Ann Nucl Med. 2019;33:545–53.
Santos A, Mattiolli A, Carvalheira JB, Ferreira U, Camacho M, Silva C, et al. PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2020;8:13.
Brito AET, Mourato FA, de Oliveira RPM, Leal ALG, Filho PJA, de Filho JLL. Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med. 2019;33:344–50.
Puca L, Vlachostergios PJ, Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med. 2019;9:a030593.
Bakht MK, Lovnicki JM, Tubman J, Stringer KF, Chiaramonte J, Reynolds MR, et al. Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for 18f-FDG imaging of PSMA-suppressed tumors. J Nucl Med. 2020;61:904–10.
Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, et al. Poor Outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2:670–6.
Komek H, Can C, Yilmaz U, Altindag S. Prognostic value of 68 Ga PSMA I and T PET/CT SUV parameters on survival outcome in advanced prostat cancer. Ann Nucl Med. 2018;32:542–52.
Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31:709–17.
Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94.
Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau AS, et al. PET/CT and biochemical recurrence of prostate adenocarcinoma: added value of 68Ga-PSMA-11 when 18Ffluorocholine is non-contributive. Prog Urol. 2017;27:474–81.
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-Fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–94.
Conflict of interest
There are no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yildirim, Ö.A., Gündoğan, C., Can, C. et al. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients. Ann Nucl Med (2021). https://doi.org/10.1007/s12149-021-01594-8
- Prostate cancer
- Prostate-specific antigen
- Gleason score